Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in CDY?
Cellmid Ltd: THE INVESTMENT CASE

Cellmid's Maria Halasz discussed growing revenue streams at Proactive's CEO Sessions

Maria Halasz discussed rapidly growing hair care sales at Proactive's CEO Sessions.
Cellmid's Maria Halasz with investors at Proactive's CEO Sessions
INVESTMENT OVERVIEW: CDY The Big Picture
Maria Halasz, chief executive, presenting at Proactive's CEO Sessions

Cellmid's (ASX:CDY) chief executive, Maria Halasz, joined Proactive's CEO Sessions in Sydney on Tuesday 3rd October and Melbourne on Tuesday 4th October.

The company is growing revenues from sales of its hair care products in the U.S.

50% discount on all evolis products. The code Proinvestovs50 will be valid until 13th October 2017.

To claim the discount, put the code in at checkout and the payment amount will automatically be adjusted to 50%.

Please note this code will work on the www.evolisprofessional.com.au and www.evolisproducts.com.au websites for 1 week only.

ACCESS THE FULL PRESENTATION HERE


 

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

picture of human skeleton
July 21 2017
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use